Abstracts tagged "Dendritic cells"

Abstract Number: 845 • 2018 ACR/ARHP Annual Meeting
New Insights in Lupus Dermatitis: Differential Regulation and Roles of Tissue-Resident Dendritic Cell Subsets in the Pathogenesis of Autoimmune Skin Inflammation
Ram R. Singh, Miguel-Angel Gutierrez, Peter Kim, Darshan Randhawa, Rachael Philips, Jennifer K. King and Anna Eriksson, Autoimmunity and Tolerance Laboratory, Department of Medicine/Rheumatology, UCLA, Los Angeles, CA
Background/Purpose: Acquired or self antigens in tissues are taken to lymphoid organs to elicit protective immunity or tolerance, respectively. This is accomplished by dendritic cells…
Abstract Number: 1018 • 2018 ACR/ARHP Annual Meeting
Tofacitinib Impairs Monocyte-Derived Dendritic Cell Differentiation in Rheumatoid Arthritis and Psoriatic Arthritis.
Viviana Marzaioli¹, Mary Canavan¹, Achilleas Floudas¹, Siobhan C. Wade¹, Candice Low², Douglas J. Veale² and Ursula Fearon¹, ¹Molecular Rheumatology, School of Medicine, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland, ²Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin, Ireland
Background/Purpose: Tofacinitib (Pfizer) is an oral Janus kinase inhibitor, recently approved for the treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Although its mechanism…
Abstract Number: 4 • 2017 ACR/ARHP Annual Meeting
Downregulation of microRNAs in Plasmacytoid Dendritic Cells Is Associated with a Type I Interferon Signature in Systemic Lupus Erythematosus and Antiphospholipid Syndrome
Lucas L. van den Hoogen¹, Joel A.G. van Roon^2,3, Ruth D.E. Fritsch-Stork⁴, Cornelis P.J. Bekker¹, Aridaman Pandit¹, Marzia Rossato⁵ and Timothy R.D.J. Radstake¹, ¹Rheumatology and Clinical Immunology, Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Laboratory for Translational immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Department of Rheumatology & Clinical Immunology, Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: The most prominent alteration in the immune system of patients with SLE is a type I interferon (IFN) signature, which we recently also reported…
Abstract Number: 861 • 2017 ACR/ARHP Annual Meeting
CD11b+Gr1dim tolerogenic Dendritic Cell-like Cells Suppress the Progression of Interstitial Lung Disease in SKG Mice
Sho Sendo¹, Jun Saegusa¹, Hirotaka Yamada², Yoshihide Ichise², Ikuko Naka³, Yo Ueda², Takaichi Okano², Soshi Takahashi⁴, Kengo Akashi⁵, Akira Onishi⁶ and Akio Morinobu⁴, ¹Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Department of Rheumatology and Clinical immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ³Department of Clinical Pathology and Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁴Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁵Department of Rheumatology and Clinical Immnology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁶Department for Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan
CD11b+Gr1dim tolerogenic Dendritic Cell-like Cells Suppress the Progression of Interstitial Lung Disease in SKG Mice Background/Purpose: SKG mice develop interstitial lung disease (ILD) resembling rheumatoid arthritis-associated…
Abstract Number: 1064 • 2017 ACR/ARHP Annual Meeting
Characterization of Human Tolerogenic Dendritic Cells Generated with Protein Kinase C Inhibitor and Induction from Patients with Autoimmune Diseases
Hitoshi Hasegawa¹, Takuya Matsumoto¹, Endy Adnan², Jun Ishizaki¹, Koichiro Suemori¹ and Masaki Yasukawa¹, ¹Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime, Japan, ²Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime, Japan
Background/Purpose: Tolerogenic dendritic cells (tDCs) are a promising therapeutic tool for specific induction of immunological tolerance. Human tDCs can be generated ex vivo using various…
Abstract Number: 1338 • 2017 ACR/ARHP Annual Meeting
Important Role of CD11c+ Dendtritic Cells in Inflammatory Arthritis
Antonia Puchner¹, Victoria Saferding¹, Michael Bonelli², Harald Leiss³, Gerhard Krönke⁴, René Pfeifle⁵, Josef S. Smolen⁶, Kurt Redlich⁷ and Stephan Blüml⁶, ¹Medical University of Vienna, Austria, Vienna, Austria, ²Rheumatology, Medical University of Vienna, Vienna, Austria, ³Rheumatology, Medical University Vienna, Vienna, Austria, ⁴Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany., Erlangen, Austria, ⁵Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁶Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ⁷Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Dendritic cells (DCs) are important antigen presenting cells (APCs) and therefore they play an important role in bridging the innate and the adaptive immune…
Abstract Number: 1579 • 2017 ACR/ARHP Annual Meeting
Monocyte-Derived Dendritic Cells (MDDCs) from Spondyloarthritis (SpA) Patients Exhbit a Coordinated Downregulation of the Cholesterol (chol) Biosynthesis Pathway That Relates to Lipid Overload
Maxime Breban¹, Clémence Desjardin², Emmanuel Chaplais³, Alice Talpin³, Felicie Costantino⁴, Christophe Hue³, Aude Jobart-Malfait⁵, Benoit Maury⁶, Stanislas Grassin-Delyle³, Nelly Bonilla⁷, Ariane Leboime⁸, Roula Said Nahal⁹, Franck Letourneur⁷, Sébastien Jacques⁷, Anne Boland¹⁰, Jean-François Deleuze¹⁰, Gilles Chiocchia¹¹ and Henri-Jean Garchon^3,6,12, ¹Rheumatology, Ambroise Paré Hospital (AP-HP), Versailles Saint Quentin en Yvelines University, INSERM UMR1173, Boulogne-Billancourt, France, ²INSERM UMR1173, Montigny-le-Bretonneux, France, ³Inserm U1173, Montigny-le-Bretonneux, France, ⁴Hôpital Universitaire Ambroise Pare, Paris, France, ⁵INSERM-U1173, University of Versailles Saint-Quentin-en-Yvelines, France, Montigny-le-Bretonneux, France, ⁶University of Versailles Saint-Quentin, Simone Veil school of Health Sciences, Montigny-le-Bretonneux, France, ⁷Institut Cochin, Inserm U1016, Paris, France, ⁸Ambroise Paré Hospital Division of Rheumatology, Assistance Publique des Hopitaux de Paris, Boulogne-Billancourt, France, ⁹Ambroise Paré Hospital, Boulogne-Billancourt, France, ¹⁰Centre National de Recherche en Génomique Humaine, Evry, France, ¹¹Service d'Immunologie, Ambroise Paré Hospital, University of Versailles Saint-Quentin-en-Yvelines, Boulogne, France, Boulogne-Billancourt, France, ¹²Ambroise Paré Hospital Division of Genetics, AP-HP, Boulogne-Billancourt, France
Background/Purpose: Gene expression studies are useful to investigate the pathogenesis of complex diseases. The critical role of antigen-presenting cells such as dendritic cells (DCs) being…
Abstract Number: 1656 • 2017 ACR/ARHP Annual Meeting
Type I Interferon Drives the Dysregulation of Plasmacytoid and Myeloid Dendritic Cells in Systemic Lupus Erythematosus and Antiphospholipid Syndrome
Lucas L. van den Hoogen¹, Aridaman Pandit¹, Giovanni Palla², Marzia Rossato³, Ruth D.E. Fritsch-Stork⁴, Joel A.G. van Roon⁵ and Timothy R.D.J. Radstake¹, ¹Rheumatology and Clinical Immunology, Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology and Clinical Immunology, Laboratory of Translational Medicine, University Medical Center Utrecht, Utrecht, Netherlands, ³Department of Rheumatology & Clinical Immunology, Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Dendritic cells (DC) are the sentinel cells of the immune system that potently activate T-cells, making them important players in the pathophysiology of systemic…
Abstract Number: 1948 • 2017 ACR/ARHP Annual Meeting
TNF-α Overrides the Ability of RANK Ligand to Induce Osteoclast Differentiation of Classical Circulating Precursors
Cecilia Ansalone¹, Flavia Sunzini¹, Caitlin Duncan¹, Sabarinadh Chilaka¹, Iain B. McInnes² and Carl S. Goodyear³, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²University of Glasgow, Glasgow, United Kingdom, ³Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: TNF-α is well known to be involved in inflammatory-induced bone destruction. This is widely supported by clinical studies showing reduced bone pathology after anti-TNF-α…
Abstract Number: 2576 • 2017 ACR/ARHP Annual Meeting
Caspase 8 in Dendritic Cells Suppresses IRF5 Activation through Endosomal TLR Signaling to Prevent SLE-like Disease
FuNien Tsai¹, Harris Perlman² and Carla Cuda², ¹Medicine-Rheumatology, Northwestern University-Feinberg School of Medicine, Chicago, IL, ²Department of Medicine Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Previous studies implicate dendritic cells (DCs) in the pathogenesis of systemic lupus erythematosus (SLE), yet the mechanisms underlying this involvement are not yet clear.…
Abstract Number: 2616 • 2017 ACR/ARHP Annual Meeting
Mesenchymal Stem Cells Induce CD1c+ Tolerogenic Dendritic Cells Via up-Regulating FLT3L in Systemic Lupus Erythematosus
Xinran Yuan¹, Dandan Wang² and Lingyun Sun³, ¹Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ²Department of Rheumatology and immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ³Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital, Nanjing University Medical School, nanjing, China
Background/Purpose: Several tolerogenic dendritic cell (DC) subsets have been identified in human such as CD1c+ DCs, which could be elevated by injection of Flt-3 ligand…
Abstract Number: 2704 • 2017 ACR/ARHP Annual Meeting
Skin Migratory Dendritic Cells Targeted and Tolerized By Calcitriol-Peptide Liposomes Supress Antigen-Specific Autoreactive T Cell Expansion and Memory Differentiation to Regulate Autoimmune Arthritis
Ryan Galea^1,2, Hendrik Nel^1,2, Meghna Talekar^1,2, Suzanne Cole³, Karyn Cochlin⁴, Shannon Hitchcock⁵, Bijun Zeng^1,2, Suman Yekollu^1,2, Jamie Rossjohn⁶, Hugh Reid⁷, Ravi Malaviya⁵, Dave Shealy⁸, Brendan O'Sullivan^1,2 and Ranjeny Thomas^1,2, ¹Dendright Pty Ltd, Brisbane, Australia, ²University of Queensland Diamantina Institute, Brisbane, Australia, ³Immunology, Janssen Research and Development, Spring House, PA, ⁴Immunology, Janssen Research and Development, Springhouse, PA, ⁵Janssen Research and Development, Springhouse, PA, ⁶Infection and Immunity Program, Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia, ⁷Monash University, Melbourne, Australia, ⁸Janssen Research and Development, Spring House, PA
Background/Purpose: Current treatments to control autoimmune arthritis and vasculitis use broadly immunosuppressive drugs, associated with undesirable side effects. Antigen-specific immunological tolerance strategies are preferable to…
Abstract Number: 2776 • 2017 ACR/ARHP Annual Meeting
Plasmacytoid Dendritic Cells in Systemic Fibrosis: Pathogenic Role in Bleomycin-Induced Fibrosis Model and Correlation with Disease in Patients with Systemic Sclerosis
Suzanne Kafaja¹, Isela Valera², Anagha Divekar³, Rajan Saggar⁴, Dinesh Khanna⁵, Daniel E. Furst⁶ and Ram R. Singh⁷, ¹Department of Internal Medicine, University of California Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, ²Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, ³Biolegend, Sa Diego, CA, ⁴Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵University of Michigan, Ann Arbor, MI, ⁶David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁷Autoimmunity and Tolerance Laboratory, Department of Medicine/Rheumatology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA
Background/Purpose: Fibrosis is the end-result of most inflammatory conditions, but its pathogenesis remains unclear. Studies in patients and animal models suggest a role for T-cells…
Abstract Number: 2087 • 2016 ACR/ARHP Annual Meeting
A Type I Interferon Signature in Monocytes and Decreased Levels of Circulating Plasmacytoid Dendritic Cells in Patients with Primary Antiphospholipid Syndrome
Lucas L. van den Hoogen¹, Ruth D.E. Fritsch-Stork², Marjan A. Versnel³, Ronald H.W.M. Derksen⁴, Joel A.G. van Roon^5,6 and Timothy R.D.J. Radstake^5,6, ¹Rheumatology and Clinical Immunology, Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Immunology, Erasmus Medical Center, Rotterdam, Netherlands, ⁴Departments of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Laboratory of Translational Immunology, UMC Utrecht, Utrecht, Netherlands, ⁶Department of Rheumatology & Clinical Immunology, UMC Utrecht, Utrecht, Netherlands
Background/Purpose: In several autoimmune diseases, most notably in systemic lupus erythematosus (SLE), a type I interferon (IFN) signature has been described. This signature is thought…
Abstract Number: 2262 • 2016 ACR/ARHP Annual Meeting
CR6086 a New Potent EP4 Receptor Antagonist with Immunomodulatory Activities
Tiziana Piepoli¹, Daniele Maggioni², Silvia Zerbi¹, Anna Stucchi¹, Laura Mennuni¹, Marco Lanza¹, Gianfranco Caselli¹ and Lucio Claudio Rovati¹, ¹Rottapharm Biotech, Monza, Italy, ²School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
Background/Purpose: In the early phase of rheumatoid arthritis (RA), PGE2 recruits different immune cells from the blood stream into target tissues. Via the EP4 receptor,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].